Click here to go to the previous page
EDC Insights: Before, During, and After
Program Code:
334
Date:
Wednesday, June 26, 2013
Time:
10:15 AM to 11:45 AM
EST
CHAIR
:
Maryanne C. Nicosia,
MS (SCHNON), Director, Clinical Data Management,
Neurocrine Biosciences Inc., United States
I have over 15 years of industry experience, particularly in the area of Data Management, and I have worked on the CRO as well as the sponsor side. I have managed trials with over 3000 subjects, and I recently oversaw the selection, validation, and in-house implementation of an EDC system.
|
SPEAKER
(S):
Kent Mahoney,
MBA (SPKNON), Director,
Soltex Consulting LLP, United States
Kent Mahoney is a Director with Soltex Consulting, responsible for solution design and client relationship management. Prior to Soltex, Kent led consulting and outsourcing engagements for Fortune 500 companies, including numerous change management and process improvement initiatives.
|
Patrick Chassaigne, Medidata Solutions Worldwide, United States
Toby Odenheim,
MBA (SPKNON), Director, IT Services,
SynteractHCR, United States
Toby has over 15 years of industry experience. His responsibilities include oversight for Synteract's clinical & safety systems. He holds an MBA, and a bachelor’s degree in biology, as well as professional certificates in Oracle Database Administration and Industrial Biotechnology from UCSD.
|
Description
This symposium will provide multiple perspectives on selecting, implementing, and getting the most out of an EDC system. Insight will be provided on the factors to consider and the critical questions to ask in order to choose the best EDC platform for an organization or clinical study. Attendees will also learn to determine which EDC-related challenges can be fixed through process re-engineering and change management, which issues truly necessitate switching to a new system, and the challenges and costs associated with moving to a new system. Finally, attendees will hear about current trends for using alternative EDC solutions in postmarketing studies.